Interleukin 15 protects against toxicity and potentiates antitumor activity of fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer

Cancer Research

Volumn 58, Issue 8, 1998, Pages 1695-1699

  Cao, Shousong ^a,c   Troutt, Anthony B ^b   Rustum, Youcef M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b AMGEN INC   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 15; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER TRANSPLANTATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GASTROINTESTINAL TOXICITY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DIARRHEA; FEMALE; FLUOROURACIL; INTERLEUKIN-15; INTERLEUKIN-2; LEUCOVORIN; RATS; RATS, INBRED F344; STOMATITIS; WEIGHT LOSS;

EID: 0032522473     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Kemeny, N. Role of chemotherapy in the treatment of colorectal carcinoma. Semin. Surg. Oncol., 3: 190-214, 1987.
2. Poon, M. A., O'Connell, M. J., Wieand, H. S., Krook, J. E., Gerstner, J. B., Tschetter, L. K., Levitt, R., Kardinal, C. G., and Mailliard, J. A. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J. Clin. Oncol., 9: 1967-1972, 1991.
3. Petrelli, N., Douglass, H. O., Jr., Herrera, L., Russell, D., Stablein, D. M., Bruckner, H. W., Mayer, R. J., Schinella, R., Green, M. D., Muggia, F. M., Megibow, A., Greenwald, E. S., Bukowski, R. M., Harris, J., Levin, B., Gaynor, E., Loutfi, A., Kalser, M. H., Barkin, J. S., Benedetto, P., Woolley, P. V., Nauta, R., Weaver, D. W., and Leichman, L. P. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized Phase III trial. J. Clin. Oncol., 7: 1419-1426, 1989.
4. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol., 10: 896-903, 1992.
5. Mansoni, S. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet, 345: 939-949, 1995.
6. Cao, S., Frank, C. and Rustum, Y. M. Role of fluoropyrimidine schedule and (6R,S)-leucovorin dose in a preclinical animal model of colorectal carcinoma. J. Natl. Cancer Inst., 88: 430-436, 1996.
7. Azzarà, A., Carulli, G., Rizzuti-Gullaci, A., Minnucci, S., Capochiani, E., and Ambrogi, F. Motility of rhG-CSF-induced neutrophils in patients undergoing chemotherapy: evidence for inhibition detected by image analysis. Br. J, Haematol., 92: 161-168, 1996.
8. Bezwoda, W. R., Dansey, R., Seymour, L., and Glencross, D. Non-cryopreserved limited number (1 or 2) peripheral blood progenitor cell (PBPC) collections following GCSF administration provide adequate hematologic support for high dose chemotherapy. Hematol. Oncol., 12: 101-110, 1994.
9. Masucci, G. New clinical applications of granulocyte-macrophage colony-stimulating factor. Med. Oncol. (Lond.), 13: 149-154, 1996.
10. Petrelli, N. J., Rodriguez-Bigas, M., Rustum, Y., Herrera, L., and Creaven, P. Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma. Cancer (Phila.), 72: 1543-1546, 1993.
11. Grabstein, K. H., Eisenman, J., Shanebeck, K., Rauch, K., Srinivasan, S., Fung, V., Beers, C., Richardson, J., Schoenborn, M. A., Ahdieh, M., Johnson, L., Alderson, M. R., Watson, J. D., Anderson, D. M., and Giri, J. G. Clone of a T cell growth factor that interacts with the β chain of the interleukin-2 receptor. Science (Washington DC), 264: 965-968, 1994.
12. Carson, W. E., Giri, J. G., Lindemann, M. J., Linett, M. L., Ahdieh, M., Paxton, R., Anderson, D., Eisenman, J., Grabstein, K., and Caligiuri, M. A. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of IL-2 receptor. J. Exp. Med., 180: 1395-1403, 1994.
13. Armitage, R. J., Macduff, B. M., Eisenman, J., Paxton, R., and Grabstein, K. H. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J. Immunol., 154: 483-490, 1995.
14. Giri, J. G., Ahdied, M., Eisenman, J., Shanebeck, K., Grabstein, K., Kumaki, S., Namen, A., Park, L. S., Cosman, D., and Anderson, D. Utilization of the β and γ chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J., 13: 2822-2830, 1994.
15. Horseman, N. D., Yu-Lee, L. Y. Transcriptional regulation by the helix bundle peptide hormones: growth hormone, prolactin, and hematopoietic cytokines. Endocr. Rev., 16: 2822-2830, 1994.
16. Mohamadzadeh, M., Takashima, A, Dougherty, I., Knop, J., Bergstresser, P. R., and Cruz, P. D., Jr. Ultraviolet B radiation up-regulates the expression of IL-15 in human skin. J. Immunol., 155: 4492-4496, 1995.
17. Giri, J. G., Kumaki, S., Ahdieh, M., Friend, D. J., Loomis, A., Shanebeck, K., Dubose, R., Cosman, D., Park, L. S., and Anderson, D. M. Identification and cloning of a novel IL-15 binding protein that is structurally related to the α chain of the IL-2 receptor. EMBO J., 14: 3654-3663, 1995.
18. Reinecker, H-C., MacDermott, R. P., Mirau, S., Dignass, A., and Podolsky, D. K. Intestinal epithelial cells both express and respond to interleukin 15. Gastroenterology, 111: 1706-1713, 1996.
19. Cao, S., Rustum, Y. M., and Spector, T. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res., 54: 1507-1510, 1994.
20. Rustum, Y. M. Toxicity and antitumor activity of 5-fluorouracil in combination with leucovorin. Role of dose schedule and route of administration of leucovorin. Cancer (Phila.), 63 (Suppl. 6): 1013-1017, 1989.
21. Doherty, T. M., Seder, R. A., and Sher, A. Induction and regulation of interleukin-15 expression in murine macrophages. J. Immunol., 156: 735-741, 1996.
22. Giri, J. G., Anderson, D. M., Kumaki, S., Park, L. S., Grabstein, K. H., and Cosman, D. IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2. J. Leuk. Biol., 57: 763-766, 1995.
23. Leclercq, G., Debacker, V., Smedt, M. D., and Plum, J. Differential effects of interleukin-15 and interleukin-2 on differentiation of bipotential T/natural killer progenitor cells. J. Exp. Med., 184: 325-336, 1996.
24. Munger, W., Dejor, S. Q., Jeyasslan, R., Sr., Torley, L. W., Grabstein, K. H., Eisenman, J., Paxton, R., Cox, T., Wick, M. M., and Kerwar, S. S. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell. Immunol., 165: 283-293, 1995.
25. Kennedy, M., Park, L. S. Characterization of interleukin-15 (IL-15) and the IL-15 receptor complex. J. Clin. Immunol., 16: 134-143, 1996.
26. Gamero, A. M., Ussery, D., Reintgen, D. S., Puleo, C. A., and Djeu, J. Y. Interleukin-15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD 18-dependent, perforin-related mechanism. Cancer Res., 55: 4988-4994, 1995.
27. Harris, J. E. Suppression of human immune response. In: J. E. Harris and J. G. Sinkovics (eds.), The Immunology of Malignant Disease, pp. 370-409. St. Louis: C. V. Mosby Co., 1976.
28. Street, N. E., and Mosmann, T. R. Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J., 5: 171-177, 1991.
29. Vieweg, J., and Gilboa, E. Consideration for the use of cytokine-secretion tumor cell preparations for cancer treatment. Cancer Invest., 13: 193-201, 1995.
30. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., Seipp, C. A., Simpson, C. G., and White, D. E. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med., 316: 889-897, 1987.
31. Rosenberg, S. A., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H., and White, D. E. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. J. Am. Med. Assoc., 271: 907-913, 1994.
32. Goey, S. H., Gratama, J. W., Primrose, J. N., Ward, U., Mertelsmann, R. H., Osterwalder, B., Verweij, J., and Stoter, G. Interleukin 2 and interferon α-2α do not improve antitumor activity of 5-fluorouracil in advanced colorectal cancer. Br. J. Cancer, 74: 2018-2023, 1996.
33. Gebbia, V., Testa, A., Majello, E., Cannata, G., Tirrito, M. L., Mastrandrea, G., Feo, M., Bajardi, G. Colucci, G., and Gebbia, N. Subcutaneous low-dose interleukin 2 and intravenous 5-fluorouracil plus high-dose levofolinic acid as salvage treatment for metastatic colorectal carcinoma. Anticancer Drugs, 7: 386-391, 1996.